AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16189333 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 0.5% bupivacaine with midazolam 50 microg x kg(‐1)
Number of subjects: 40
Study 16189333 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of 0.5% bupivacaine
Number of subjects: 40
Study 14621278 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisecretory factor (AF) treatment as an additive to conventional UC medication
Number of subjects: 20
Study 10804075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (up to 100 mg/day)
Number of subjects: 97
Study 10804075 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (low vs. regular doses)
Number of subjects: 97
Study 8796796 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (upright stationary cycling for 30 min at 60% VO2max)
Number of subjects: 11
Study 1298491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg
Number of subjects: 30
Study 1298491 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1,000 mg
Number of subjects: 30
Study 6724670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 0
Study 6724670 — intervention group
Group type: COMPARATOR
Intervention: Referred Care
Number of subjects: 0
Study 30591393 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of the orbicularis oris muscle and dissection of both origin and abnormal insertion of the nasalis muscle (Group 2B)
Number of subjects: 45
Study 30591393 — intervention group
Group type: COMPARATOR
Intervention: Repair of the orbicularis muscle only (Group 1)
Number of subjects: 45
Study 30591393 — intervention group
Group type: COMPARATOR
Intervention: Repair of the orbicularis oris muscle and dissection and repair the origin of the nasalis muscle (Subgroup A)
Number of subjects: 45
Study 27422973 — intervention group
Group type: EXPERIMENTAL
Intervention: HPG/PEG/PG
Number of subjects: 94
Study 27422973 — intervention group
Group type: COMPARATOR
Intervention: O/CMC
Number of subjects: 94
Study 27422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 94
Study 25362105 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing gait speed
Number of subjects: 135
Study 25362105 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing step length
Number of subjects: 135
Study 25362105 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in swing time at second follow-up (2.8±0.6 years)
Number of subjects: 135
Study 25362105 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in double support phase at second follow-up (2.8±0.6 years)
Number of subjects: 135
Study 24075226 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 301
Study 24075226 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian menthol smokers
Number of subjects: 301
Study 24075226 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation
Number of subjects: 301
Study 21307076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insulin
Number of subjects: 52
Study 21307076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19822770 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum urate concentration
Number of subjects: 800
Study 19822770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid urate concentration
Number of subjects: 800
Study 19822770 — intervention group
Group type: COMPARATOR
Intervention: Subjects not treated with alpha‐tocopherol (2000 IU/d)
Number of subjects: 800
Study 19822770 — intervention group
Group type: COMPARATOR
Intervention: Subjects treated with alpha‐tocopherol (2000 IU/d)
Number of subjects: 800
Study 17166393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 15288319 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day course)
Number of subjects: 108
Study 15288319 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics (10-day course)
Number of subjects: 108
Study 11402407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach (group II)
Number of subjects: 89
Study 11402407 — intervention group
Group type: COMPARATOR
Intervention: Standard medial parapatellar arthrotomy (group I)
Number of subjects: 89
Study 9007457 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0
Study 9007457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8479715 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye muscle reflectivity measurement in patients with Graves ophthalmopathy
Number of subjects: 16
Study 8479715 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye muscle reflectivity measurement in responders to treatment
Number of subjects: 16
Study 8479715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value of 40% for eye muscle reflectivity
Number of subjects: 16
Study 3317344 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccine
Number of subjects: 0
Study 3317344 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (20 micrograms)
Number of subjects: 0
Study 3317344 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly purified recombinant vaccines
Number of subjects: 0
Study 3317344 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccine
Number of subjects: 0
Study 31070807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical EMAX model
Number of subjects: 0
Study 31070807 — intervention group
Group type: EXPERIMENTAL
Intervention: EMAX model
Number of subjects: 0
Study 31070807 — intervention group
Group type: COMPARATOR
Intervention: Independent model
Number of subjects: 0
Study 30479829 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning resource co-produced with African-Caribbean stakeholders
Number of subjects: 40
Study 30479829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 6990
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor with moderate CYP3A inducers
Number of subjects: 6990
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor with moderate CYP3A inhibitors
Number of subjects: 6990
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in habitual smokers
Number of subjects: 6990
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor at treatment initiation (visit 1)
Number of subjects: 6990
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in Asian patients
Number of subjects: 6990
Study 27191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in Black patients
Number of subjects: 6990
Study 25038293 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychoeducation intervention (n=33)
Number of subjects: 67
Study 25038293 — intervention group
Group type: COMPARATOR
Intervention: Online attention-matched control information (n=34)
Number of subjects: 67
Study 22127409 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser endourethrotomy (HLU)
Number of subjects: 50
Study 22127409 — intervention group
Group type: COMPARATOR
Intervention: Optical internal urethrotomy (OIU)
Number of subjects: 50
Study 19803607 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with PTSD
Number of subjects: 144
Study 19803607 — intervention group
Group type: COMPARATOR
Intervention: Adolescents without PTSD
Number of subjects: 144
Study 19803607 — intervention group
Group type: COMPARATOR
Intervention: Mothers
Number of subjects: 144
Study 19803607 — intervention group
Group type: COMPARATOR
Intervention: Fathers
Number of subjects: 144
Study 17609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 0, 2, 6, 2, 0 ng ml(‐1)
Number of subjects: 40
Study 17609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 6, 2, 0, 2, 6 ng ml(‐1)
Number of subjects: 40
Study 17609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious stimulus
Number of subjects: 40
Study 15621318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound indentation method
Number of subjects: 105
Study 15621318 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy, non‐irradiated subjects
Number of subjects: 105
Study 12192713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of diluted injectable quinimax at a dose of 12.5 mg/kg every 12 hours for 72 hours.
Number of subjects: 64
Study 12192713 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal (IR) administration of diluted injectable quinimax at a dose of 15 mg/kg every 12 hours for 72 hours.
Number of subjects: 64
Study 9824925 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer in a wheelchair (SAQ‐Self)
Number of subjects: 120
Study 9824925 — intervention group
Group type: COMPARATOR
Intervention: Peer in a wheelchair (SAQ‐Others)
Number of subjects: 120
Study 8130028 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (1200 mg in two divided doses)
Number of subjects: 20
Study 8130028 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 2528306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium bolus dose 0.15 mg/kg
Number of subjects: 72
Study 2528306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium bolus dose 0.25 mg/kg
Number of subjects: 72
Study 2528306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium bolus dose (both 0.15 mg/kg and 0.25 mg/kg) with no additional mivacurium
Number of subjects: 72
Study 2528306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion adjusted to depress twitch response by approximately 95%
Number of subjects: 72
Study 2528306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion rates
Number of subjects: 72
Study 2528306 — intervention group
Group type: COMPARATOR
Intervention: Anesthetic technique (balanced vs enflurane)
Number of subjects: 72
Study 1161344 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (oral sodium bicarbonate treatment when base excess > -8 mEq/liter or suspected acidosis)
Number of subjects: 26
Study 1161344 — intervention group
Group type: COMPARATOR
Intervention: Group B (oral sodium bicarbonate treatment maintaining base excess within 1 SD of normal)
Number of subjects: 26
Study 1161344 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (oral sodium bicarbonate treatment)
Number of subjects: 26
Study 1161344 — intervention group
Group type: COMPARATOR
Intervention: Group B (oral sodium bicarbonate treatment)
Number of subjects: 26
Study 1161344 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 26
Study 1161344 — intervention group
Group type: EXPERIMENTAL
Intervention: AGA infants
Number of subjects: 26
Study 31816049 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation medication
Number of subjects: 482
Study 31816049 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 482
Study 31816049 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit attempts
Number of subjects: 482
Study 31816049 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit motivation
Number of subjects: 482
Study 31816049 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of smoking cessation medications
Number of subjects: 482
Study 31816049 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of smoking cessation counseling
Number of subjects: 482
Study 31138068 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 118
Study 31138068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 28524457 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation (MCS) at 100%, 83.3%, 66.7%, or 50% of the time in 30-min intervals
Number of subjects: 6
Study 25524432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4447
Study 25524432 — intervention group
Group type: COMPARATOR
Intervention: Metformin/Sulfonylurea (Control)
Number of subjects: 4447
Study 25524432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Women)
Number of subjects: 4447
Study 25524432 — intervention group
Group type: COMPARATOR
Intervention: Metformin/Sulfonylurea (Control, Women)
Number of subjects: 4447
Study 25524432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Men)
Number of subjects: 4447
Study 25524432 — intervention group
Group type: COMPARATOR
Intervention: Metformin/Sulfonylurea (Control, Men)
Number of subjects: 4447
Study 23499569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely-X Veneer resin-coating with a seating load of 5N
Number of subjects: 288
Study 23499569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely-X Veneer resin-coating with a seating load of 30N
Number of subjects: 288
Study 23499569 — intervention group
Group type: COMPARATOR
Intervention: Uncoated controls
Number of subjects: 288
Study 21130194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic H1N1 vaccine first, followed by seasonal vaccine 21 days later
Number of subjects: 151
Study 21130194 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal vaccine first, followed by pandemic H1N1 vaccine 21 days later
Number of subjects: 151
Study 21130194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines administered simultaneously
Number of subjects: 151
Study 21130194 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 151
Study 19943971 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 72
Study 19943971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity supervised exercise program
Number of subjects: 72
Study 19943971 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and vigorous intensity exercise
Number of subjects: 72
Study 19943971 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the REACH program
Number of subjects: 72
Study 19943971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19943971 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity supervised exercise program
Number of subjects: 72
Study 17296639 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term targeted therapy
Number of subjects: 70
Study 17296639 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 70
Study 15219636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol ApEn in depressed men
Number of subjects: 30
Study 15219636 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH ApEn in depressed men
Number of subjects: 30
Study 15219636 — intervention group
Group type: COMPARATOR
Intervention: Cortisol and ACTH levels derived from cosinor analysis
Number of subjects: 30
Study 16113556 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (two doses, 24 hours apart)
Number of subjects: 0
Study 10493479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic retrocolic gastrojejunostomy
Number of subjects: 87
Study 10493479 — intervention group
Group type: COMPARATOR
Intervention: No gastrojejunostomy
Number of subjects: 87
Study 8709687 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg daily, intramuscularly, for three doses)
Number of subjects: 122
Study 8709687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 1770216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 2 gm/day for 30 days
Number of subjects: 10
Study 1770216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1770216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 10
Study 6800629 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal feeding
Number of subjects: 0
Study 6800629 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0
Study 6800629 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition (oral feeding)
Number of subjects: 0
Study 31086050 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (HDF)
Number of subjects: 404
Study 31086050 — intervention group
Group type: COMPARATOR
Intervention: Low-flux Hemodialysis (HD)
Number of subjects: 404
Study 28374218 — intervention group
Group type: EXPERIMENTAL
Intervention: BEST MOOD intervention
Number of subjects: 64
Study 28374218 — intervention group
Group type: COMPARATOR
Intervention: PAST (treatment-as-usual)
Number of subjects: 64
Study 26745346 — intervention group
Group type: EXPERIMENTAL
Intervention: Training interventions for social skills development
Number of subjects: 0
Study 26745346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study 26745346 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish treatment group
Number of subjects: 0
Study 26745346 — intervention group
Group type: COMPARATOR
Intervention: German control group
Number of subjects: 0
Study 26745346 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger German pupils (indirect effectiveness of interventions)
Number of subjects: 0
Study 25227543 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT plus trunk restraint
Number of subjects: 22
Study 25227543 — intervention group
Group type: COMPARATOR
Intervention: mCIMT
Number of subjects: 22
Study 22782571 — intervention group
Group type: EXPERIMENTAL
Intervention: Berocca™
Number of subjects: 91
Study 22782571 — intervention group
Group type: EXPERIMENTAL
Intervention: CNE™ low dose (CNE4)
Number of subjects: 91
Study 22782571 — intervention group
Group type: EXPERIMENTAL
Intervention: CNE™ high dose (CNE8)
Number of subjects: 91
Study 22782571 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonrandomized, n=25)
Number of subjects: 91
Study 19897418 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab (400 mg/m2 initial dose, followed by seven weekly doses at 250 mg/m2)
Number of subjects: 424
Study 19897418 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 424
Study 19897418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-treated patients with acneiform rash of at least grade 2 severity
Number of subjects: 424
Study 18445258 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated interventions (STI/HIV education, condoms, facilitated HIV testing, treatment and care services)
Number of subjects: 503
Study 18445258 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated interventions
Number of subjects: 503
Study 16178492 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 225 U
Number of subjects: 702
Study 16178492 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 150 U
Number of subjects: 702
Study 16178492 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 75 U
Number of subjects: 702
Study 16178492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 11840116 — intervention group
Group type: COMPARATOR
Intervention: Walking velocity of 3.8 km/h and higher
Number of subjects: 39
Study 11840116 — intervention group
Group type: COMPARATOR
Intervention: Walking velocity from 1.4 to 3.0 km/h
Number of subjects: 39
Study 11840116 — intervention group
Group type: COMPARATOR
Intervention: Overall gait characteristics
Number of subjects: 39
Study 11840116 — intervention group
Group type: COMPARATOR
Intervention: Coordination measures
Number of subjects: 39
Study 10520778 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic administration
Number of subjects: 1817
Study 10520778 — intervention group
Group type: COMPARATOR
Intervention: Culprit artery with TIMI grade 3 flow
Number of subjects: 1817
Study 10520778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery
Number of subjects: 1817
Study 10520778 — intervention group
Group type: COMPARATOR
Intervention: Culprit artery PTCA with abnormal nonculprit artery flow (CTFC >= 28 frames)
Number of subjects: 1817
Study 10520778 — intervention group
Group type: COMPARATOR
Intervention: Global CTFC
Number of subjects: 1817
Study 7720766 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH-free GTN spray with low ethanol content (TL)
Number of subjects: 0
Study 7720766 — intervention group
Group type: COMPARATOR
Intervention: FCH-containing GTN spray (R)
Number of subjects: 0
Study 7720766 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH-free GTN spray with higher ethanol content (TH)
Number of subjects: 0
Study 31760536 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV self-testing with video-chat counseling
Number of subjects: 202
Study 31760536 — intervention group
Group type: COMPARATOR
Intervention: Home-based HIV self-testing
Number of subjects: 202
Study 30970430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomograms for disease-free survival (DFS)
Number of subjects: 385
Study 30970430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomograms for overall survival (OS)
Number of subjects: 385
Study 28977796 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous/Sodium Fluoride (SnF/NaF, 1,450 ppm F-, 1,090 ppm Sn2+)
Number of subjects: 20
Study 28977796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride/Stannous Chloride/Chitosan (NaF/Sn/Ch, 1,450 ppm F-, 3,500 ppm Sn2+, 0.5% Ch)
Number of subjects: 20
Study 28977796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride (NaF, 1,450 ppm)
Number of subjects: 20
Study 28977796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 20
Study 26559131 — intervention group
Group type: EXPERIMENTAL
Intervention: Active for Life Year 5 (AFLY5) intervention
Number of subjects: 95
Study 23140115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (mixture of essential oils: peppermint, basil, and helichrysum)
Number of subjects: 14
Study 23140115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rose water)
Number of subjects: 14
Study 21270184 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (home video visits with a diabetes educator and glucose uploads every 4-6 weeks)
Number of subjects: 1665
Study 21270184 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665